Copyright: ©Author(s) 2026.
World J Gastrointest Surg. Mar 27, 2026; 18(3): 114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Published online Mar 27, 2026. doi: 10.4240/wjgs.v18.i3.114569
Table 4 Comparison of survival outcomes, n (%)
| Survival rate | Control group (n = 60) | Research group (n = 64) | χ2 | P value |
| 6 months post operation | 55 (91.67) | 61 (95.31) | 0.682 | 0.409 |
| 9 months post operation | 47 (78.33) | 56 (87.50) | 1.850 | 0.174 |
| 12 months post operation | 42 (70.00) | 50 (78.13) | 1.068 | 0.302 |
- Citation: Shi JF, Xu H, Gao JF, Wu JB. Adjuvant irinotecan-apatinib therapy for recurrent/metastatic gastric cancer after surgery: A real-world evaluation. World J Gastrointest Surg 2026; 18(3): 114569
- URL: https://www.wjgnet.com/1948-9366/full/v18/i3/114569.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v18.i3.114569